TP53 mutation is associated with selective upregulation of LAG3 independent of immune infiltration and antigen-presentation signatures in WHO grade 4 glioma

Clicks: 15
ID: 327515
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #106 of 144 articles by views in Neuro-Oncology Advances

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 144 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background LAG3 has emerged as a clinically actionable immune checkpoint target in oncology, but its molecular determinants in glioma remain poorly characterized. We aimed to determine whether TP53 mutation is associated with LAG3 expression, whether this is selective among immune checkpoint genes, and whether it persists after adjustment for transcriptomic immune scores. Methods We analyzed gene expression and mutation data from the Genomic Data Commons (GDC), incorporating three datasets (TCGA, CPTAC, HCMI) into a GDC discovery cohort of WHO grade 4 glioma (n = 442). An independent GLASS dataset served as a validation cohort (n = 79). LAG3 and six additional checkpoint genes were compared between TP53-mutant and wild-type tumors using Wilcoxon rank-sum tests and adjusted linear regression with transcriptomic immune scores as covariates. Results TP53 mutation was consistently associated with elevated LAG3 expression in the GDC cohort (median difference = +0.288 log2(TPM+1), Cliff's δ = 0.289, p = 7.13 × 10⁻⁷) and replicated in the GLASS cohort (δ = 0.395, p = 0.005). Among seven checkpoint genes, only LAG3 showed significant TP53-associated upregulation after Benjamini–Hochberg correction in both cohorts. The TP53 regression coefficient was unchanged after immune score adjustment, and TP53 status was not associated with any immune score (all p ≥ 0.67). Adjustment for tumor purity and proliferation-related Hallmark programs partially attenuated but did not abolish the association. Conclusions TP53 mutation is associated with selective, immune context–independent LAG3 upregulation in grade 4 glioma, supporting TP53 mutation as a candidate stratifier for LAG3-targeted immunotherapy and motivating mechanistic studies.
Reference Key
openalex_W7207812792 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Youji Uemae, Shunichiro Miki, Erika Yamada, Alexander Zaboronok, Tadao Ohno, Eiichi Ishikawa
Are you one of these authors? Claim your profile
Journal Neuro-Oncology Advances
Year 2026
DOI
10.1093/noajnl/vdag233
URL
https://doi.org/10.1093/noajnl/vdag233
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.